Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
What is Jiangxi Xinganjiang Pharmaceutical Co PE Ratio (TTM)?
Jiangxi Xinganjiang Pharmaceutical CoBJSE:920367 70 PE Ratio (TTM) is 123.00 as of Aug. 05, 2026, which is 220% above its 10-year median of 38.42. GuruFocus rates BJSE:920367 with a GF Score™ of 70/100 and a GF Value™ of ¥11.95 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 639 Drug Manufacturers companies, Jiangxi Xinganjiang Pharmaceutical Co ranks worse than 92.96% on this metric.
BJSE:920367'
s PE Ratio (TTM) Range Over the Past 10 Years
Min: 9.18 Med: 38.42 Max: 182.35
Current: 123
During the past 10 years, the highest PE Ratio (TTM) of Jiangxi Xinganjiang Pharmaceutical Co was 182.35. The lowest was 9.18. And the median was 38.42.
BJSE:920367's PE Ratio (TTM) is ranked worse than 92.96% of 639
companies
in the Drug Manufacturers industry
Industry Median: 21.03
vs BJSE:920367: 123.00
Jiangxi Xinganjiang Pharmaceutical Co (BJSE:920367) PE Ratio (TTM) Explanation
The PE Ratio (TTM) can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. For example, if a company earns $2 a share per year, and the stock is traded at $30, the PE Ratio (TTM) is 15. Therefore it takes 15 years for the company to earn back the $30 you paid for its stock, assuming the earnings stays constant over the next 15 years.
In real business, earnings never stay constant. If a company can grow its earnings, it takes fewer years for the company to earn back the price you pay for the stock. If a company's earnings decline it takes more years. As a shareholder, you want the company to earn back the price you pay as soon as possible. Therefore, lower P/E stocks are more attractive than higher P/E stocks so long as the PE Ratio (TTM) is positive. Also for stocks with the same PE Ratio (TTM), the one with faster growth business is more attractive.
If a company loses money, the PE Ratio (TTM) becomes meaningless.
To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the PE Ratio (TTM) divided by the growth ratio. He thinks a company with a PE Ratio (TTM) equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a PE Ratio (TTM) of 20, instead of a company growing 10% a year with a PE Ratio (TTM) of 10.
Because the PE Ratio (TTM) measures how long it takes to earn back the price you pay, the PE Ratio (TTM) can be applied to the stocks across different industries. That is why it is the one of the most important and widely used indicators for the valuation of stocks.
Investors need to be aware that the PE Ratio (TTM) can be misleading a lot of times, especially when the underlying business is cyclical and unpredictable. As Peter Lynch pointed out, cyclical businesses have higher profit margins at the peaks of the business cycles. Their earnings are high and PE Ratio (TTM)s are artificially low. It is usually a bad idea to buy a cyclical business when the PE Ratio (TTM) is low. A better ratio to identify the time to buy a cyclical businesses is the PS Ratio .
PE Ratio (TTM) can also be affected by non-recurring-items such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio (TTM).
Jiangxi Xinganjiang Pharmaceutical Co PE Ratio (TTM) Related Terms
Jiangxi Xinganjiang Pharmaceutical Co PE Ratio (TTM) Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Jiangxi Xinganjiang Pharmaceutical Co PE Ratio (TTM) Chart
For the Drug Manufacturers - Specialty & Generic subindustry, Jiangxi Xinganjiang Pharmaceutical Co's PE Ratio (TTM), along with its competitors' market caps and PE Ratio (TTM) data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Jiangxi Xinganjiang Pharmaceutical Co PE Ratio (TTM) vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Jiangxi Xinganjiang Pharmaceutical Co's PE Ratio (TTM) distribution charts can be found below:
* The bar in red indicates where Jiangxi Xinganjiang Pharmaceutical Co's PE Ratio (TTM) falls into.
Jiangxi Xinganjiang Pharmaceutical Co PE Ratio (TTM) Calculation
The PE Ratio (TTM), or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). It is the most widely used ratio in the valuation of stocks.
Jiangxi Xinganjiang Pharmaceutical Co's Share Price of today is ¥20.91.
Jiangxi Xinganjiang Pharmaceutical Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥0.17.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
There are at least three kinds of PE Ratio (TTM)s used by different investors. They are Trailing Twelve Month PE Ratio (TTM) or PE Ratio (TTM) (TTM), Forward PE Ratio, or PE Ratio without NRI. A new PE Ratio (TTM) based on inflation-adjusted normalized PE Ratio (TTM) is called Shiller PE Ratio, after Yale professor Robert Shiller.
In the calculation of PE Ratio (TTM), the earnings per share used are the earnings per share over the past 12 months. For Forward PE Ratio, the earnings are the expected earnings for the next twelve months. In the case of PE Ratio without NRI, the reported earnings less the non-recurring items are used.
For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. Since it looks at the average over the last 10 years, Shiller PE Ratio is also called PE10.
Jiangxi Xinganjiang Pharmaceutical Co (BJSE:920367) has a PE Ratio (TTM) of 123.00 as of Aug. 05, 2026. Trailing 12-month P/E ratio is the ratio of share price to a company's trailing 12-month earnings per share. View historical data on Jiangxi Xinganjiang Pharmaceutical Co and its competitors. This is 220% above median its historical median of 38.42. Over the past decade, Jiangxi Xinganjiang Pharmaceutical Co's PE Ratio (TTM) has ranged from 9.18 to 182.35. According to the industry distribution chart, Jiangxi Xinganjiang Pharmaceutical Co ranks #594 out of 639 companies in the Drug Manufacturers industry, placing it in the top 93%.
Is Jiangxi Xinganjiang Pharmaceutical Co's PE Ratio (TTM) too high?
Jiangxi Xinganjiang Pharmaceutical Co's current PE Ratio (TTM) of 123.00 is 220% above median its 10-year median of 38.42. Over the past 10 years, this metric has ranged from a low of 9.18 to a high of 182.35. The Drug Manufacturers industry median PE Ratio (TTM) is 21.03. Jiangxi Xinganjiang Pharmaceutical Co's value of 123.00 is 484.9% above this industry median. Based on the distribution chart, Jiangxi Xinganjiang Pharmaceutical Co ranks #594 out of 639 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Jiangxi Xinganjiang Pharmaceutical Co has a GF Score™ of 70/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Jiangxi Xinganjiang Pharmaceutical Co's PE Ratio (TTM) compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Jiangxi Xinganjiang Pharmaceutical Co ranks #594 out of 639 companies for PE Ratio (TTM). This places Jiangxi Xinganjiang Pharmaceutical Co in the lower half of its industry. The industry median PE Ratio (TTM) is 21.03. Jiangxi Xinganjiang Pharmaceutical Co's value of 123.00 is 484.9% above this benchmark. Historically, Jiangxi Xinganjiang Pharmaceutical Co's own PE Ratio (TTM) has ranged from 9.18 to 182.35 over the past decade. While the company's 10-year median is 38.42 vs. the industry median of 21.03, Jiangxi Xinganjiang Pharmaceutical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PE Ratio (TTM) for a Drug Manufacturers company?
The median PE Ratio (TTM) among Drug Manufacturers companies is 21.03, based on 639 companies in the industry. Companies in the top quartile (top 25%) have a PE Ratio (TTM) significantly above this median, while those in the bottom quartile fall well below. However, PE Ratio (TTM) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Jiangxi Xinganjiang Pharmaceutical Co's current PE Ratio (TTM) of 123.00 is 484.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PE Ratio (TTM) mean?
A high PE Ratio (TTM) can signal that a stock is expensive relative to its fundamentals. Trailing 12-month P/E ratio is the ratio of share price to a company's trailing 12-month earnings per share. View historical data on Jiangxi Xinganjiang Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median PE Ratio (TTM) is 21.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Jiangxi Xinganjiang Pharmaceutical Co's current PE Ratio (TTM) is 123.00, which is 220% above median its own 10-year median of 38.42. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jiangxi Xinganjiang Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Jiangxi Xinganjiang Pharmaceutical Co (BJSE:920367) is currently considered Significantly Overvalued. The stock's GF Value™ is ¥11.95, compared to a current price of ¥20.91 — trading 75% above its estimated fair value. The current PE Ratio (TTM) is 123.00, which is 220% above median its 10-year median of 38.42 and 484.9% above the Drug Manufacturers industry median of 21.03. Jiangxi Xinganjiang Pharmaceutical Co's overall GF Score™ is 70/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PE Ratio (TTM) calculated?
PE Ratio (TTM) is calculated from a company's financial statements. For Jiangxi Xinganjiang Pharmaceutical Co (BJSE:920367), the current PE Ratio (TTM) is 123.00 as of Aug. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Jiangxi Xinganjiang Pharmaceutical Co (BJSE:920367) Overvalued in 2026?
Based on GuruFocus' analysis, Jiangxi Xinganjiang Pharmaceutical Co stock appears to be overvalued.
The current stock price of ¥20.91 is trading 75% above its estimated GF Value™ of ¥11.95.
GuruFocus considers Jiangxi Xinganjiang Pharmaceutical Co to be Significantly Overvalued.
Key valuation signals for BJSE:920367:
PE Ratio (TTM): 123.00 (220% above median its 10-year median of 38.42)
GF Value™: ¥11.95 vs. price of ¥20.91 (75% above fair value)
Industry Position: 484.9% above the Drug Manufacturers median (#594 of 639)
No single metric tells the full story. See the BJSE:920367 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Jiangxi Xinganjiang Pharmaceutical Co Ltd conducts research and development, production, and sales of chemical raw materials, chemical preparations, and Chinese patent medicines. The company's raw material medicine products are mainly calcium gluconate, zinc gluconate, ferrous gluconate, and other gluconate series raw material medicines. Its main chemical preparations are vitamin C chewable tablets and compound Yinqiao aminomin capsules, and Phenaminokamin Tablets.
70GF Score
Get the complete analysis for BJSE:920367
PE Ratio (TTM) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BJSE:920367 has been successfully added to your 
